An additional RCT was identified and included which compared metformin immediate-release (MIR) with metformin extended-release (MXR).65 The GDG subsequently felt that there might be relevant and important information in existence on the AE profile of these two formulations which had not been found during our search. Thus a focused call for evidence to all stakeholders was made. Following this, the GDG considered two RCTs (published in the same paper) which compared MXR against placebo,66 and to a retrospective chart review comparing immediaterelease and extended-release Consideration was also given to four abstracts; however their usefulness is limited by the small number of patients included and the lack.
